VTRS Q4 2024 Earnings — Viatris Inc. Revenue & Financial Results | Market Cap Arena

VTRSViatris Inc.

$17B

Q4 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$3.5B-8.1% YoY

Gross Profit

$1.2B34.4% margin

Operating Income

-$180M-5.1% margin

Net Income

-$517M-14.6% margin

EPS (Diluted)

$-0.43

QoQ Revenue Growth

-5.9%

Cash Flow

Operating Cash Flow

$483M

Free Cash Flow

$329M

Stock-Based Comp.

$32M

Balance Sheet

Total Assets

$41.5B

Total Liabilities

$22.9B

Stockholders' Equity

$18.6B

Cash & Equivalents

$735M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.5B	$3.8B	-8.1%
Gross Profit	$1.2B	$1.6B	-23.9%
Operating Income	-$180M	-$455M	+60.4%
Net Income	-$517M	-$766M	+32.5%

Revenue Segments

Brands

$4.5B62%

Generics

$2.8B38%

Geographic Segments

Developed Markets Segment

$2.2B61%

Greater China Segment

$523M15%

Emerging Markets Segment

$523M15%

Japan, Australia and New Zealand Segment

$338M9%